Genetic link between cannabis use and psychosis could help to identify those most at risk
#78 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians can use emerging genetic risk profiles to identify patients at elevated vulnerability to cannabis-induced psychosis, enabling more targeted counseling and risk stratification during substance use assessments. This research supports personalized medicine approaches where patients with specific genetic markers might benefit from stronger warnings against cannabis use or closer psychiatric monitoring. Understanding the genetic architecture of cannabis-psychosis risk allows providers to move beyond one-size-fits-all prevention strategies and instead counsel patients based on individual biological susceptibility.
Recent genetic research from King’s College London has identified distinct and shared genetic vulnerabilities that increase the risk of psychosis in cannabis users, suggesting that some individuals carry inherent biological susceptibility to cannabis-induced psychiatric adverse effects. This work advances our understanding of the pharmacogenetics underlying cannabis and psychosis, moving beyond the previous assumption that psychotic risk is uniform across all users. The findings have significant implications for clinical practice, as they suggest that future genetic screening could help identify high-risk patients before cannabis exposure, particularly important given the increasing availability of high-potency products and therapeutic uses of cannabis. Clinicians should consider obtaining detailed psychiatric and family histories to screen for genetic predisposition when counseling patients about cannabis use or considering it as a therapeutic option. These discoveries could eventually inform personalized medicine approaches and guide safer prescribing practices or patient counseling regarding the individualized risks of psychosis associated with cannabis consumption.
“What this genetic research tells us clinically is that we can’t keep treating cannabis as a monolithic risk factor—some patients carry genetic variants that substantially increase their psychotic vulnerability, while others in the same exposure circumstances don’t develop illness, and that distinction matters enormously for our screening and counseling conversations.”
🧠 Recent genetic studies identifying shared liability between cannabis use and psychosis risk offer intriguing possibilities for stratified prevention, yet clinicians should interpret these findings cautiously when counseling patients. The genetic correlation does not establish causation, and the clinical utility of genetic risk scores remains unproven in real-world practice, where environmental, social, and developmental factors continue to play substantial roles in psychotic illness. Additionally, most identified genetic variants confer small individual effect sizes, and polygenic prediction in diverse populations remains scientifically challenging. Rather than awaiting genetic screening tools that may not soon materialize, clinicians can apply existing knowledge by taking thorough personal and family psychiatric histories before discussing cannabis with patients, particularly those with first-degree relatives affected by psychosis, and by reinforcing that cannabis use during adolescence and early adulthood carries documented psychosis risks regardless of genetic background. The genetic perspective should complement, not replace, standard risk assessment and harm reduction
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
